+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Endometrial Cancer Market - Growth, Trends, and Forecast (2019 - 2024)

  • ID: 4520057
  • Report
  • 112 pages
  • Mordor Intelligence
until Jul 01st 2019
1 of 5


  • AstraZeneca Plc
  • Elekta AB
  • Mylan
  • Novartis AG
  • Pfizer Inc.
  • R-Pharm-US LLC.
  • MORE
Market Overview

The global endometrial cancer market is expected to register a CAGR of 4.5% over the forecast period. Factors responsible for the growth of this market include a rise in awareness about uterine diseases and their available therapies, innovation in drug development and subsequent technological advancements, and increasing healthcare expenditure. For instance, in most countries, the rate at which healthcare expenditure is increasing is higher than the rate of economic growth, and this is a trend that has been observed over the decades. The presence of equitable, responsive, and efficient health systems across the countries of North America, Europe, and Asia-Pacific has also contributed to the maximum share of GDP being utilized as healthcare expenditure. Moreover, with the increase in the number of people diagnosed with cancer, the introduction of new therapies is expected to increase the costs of cancer care. Cancer treatment can be very expensive, especially with the patients and survivors often needing long-term treatment and monitoring. Additionally, attractive healthcare insurance plans and better reimbursement rates play a vital role in increasing people’s expenditure on treatments, which is expected to drive the market studied.

However, factors, such as the adverse effects of the treatment and high toxicity of drugs are expected to hinder the market growth.

Scope of the Report

Endometrial cancer is the malignancy that develops in the layers of the cells that form the endometrium, the lining of the uterus. Women with high blood pressure, diabetes, or breast cancer are at a greater risk of being affected by endometrial cancer.

Key Market Trends

Chemotherapy is expected to hold the Highest Revenue Share in the Type of Therapy Segmentation

In the global endometrial cancer market, the chemotherapy segment is expected to witness a moderate CAGR, owing to the lesser number of drugs approved for the treatment of endometrial cancer. However, the segment is expected to hold the largest share in the type of therapy; this is due to the high adoption rate of chemotherapy when compared to radiation and surgical treatment. Besides, the chemotherapeutic agents, such as carboplatin and paclitaxel, are commonly recommended as the first line of therapy in the majority of the cancer cases, which increases demand for these products. For example, recently the US FDA approved the IXEMPRA (ixabepilone) for use in the treatment of endometrial cancer and this is expected to drive the growth of the market.

North America dominates the Market and expected to do Same in the Forecast Period

North America currently dominates the market for endometrial cancer and is expected to continue its stronghold for a few more years due to a high incidence of uterine serous carcinoma. In North America, the United States holds the largest market share. This can be majorly attributed to increasing prevalence rates of endometrial cancers. For instance, according to the American Cancer Society, it is estimated that in 2019, approximately 61,880 new cases of cancer of the uterus will be diagnosed in the United States. This, along with other factors, such as the rising awareness for the diagnosis of cancer and the presence of the developed healthcare infrastructure are expected to propel the market in the United States.

Competitive Landscape

The endometrial cancer market is moderately competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. Due to the rising prevalence of cancer, there are several products in the trails; henceforth, it is expected that few other smaller players may enter into the market. Some of the major players of the market are Bristol-Myers Squibb Company, Pfizer Inc., R-Pharm-US LLC, Elekta AB, and Varian Medical Systems, Inc., among others.

As part of this package, any purchases made up to 30th June will receive the following:

1) Free update of the report in 6 months on request 

2) Free Market Estimate sheet excel data sheet
Note: Product cover images may vary from those shown
2 of 5


  • AstraZeneca Plc
  • Elekta AB
  • Mylan
  • Novartis AG
  • Pfizer Inc.
  • R-Pharm-US LLC.
  • MORE
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Awareness about Uterine Diseases and their Available Therapies
4.2.2 Increasing Healthcare Expenditure
4.2.3 Innovation in Drug Development and Subsequent Technological Advancements
4.3 Market Restraints
4.3.1 High Cost Associated with the Treatment
4.3.2 Adverse Effects of the Treatment and High Toxicity of Drugs
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Type of Cancer
5.1.1 Endometrial Carcinoma Adenocarcinoma Carcinosarcoma Squamous Cell Carcinoma Other Types of Cancer
5.1.2 Uterine Sarcomas
5.2 By Type of Therapy
5.2.1 Immunotherapy
5.2.2 Radiation Therapy
5.2.3 Chemotherapy
5.2.4 Other Types of Therapies
5.3 By Diagnosis Method
5.3.1 Biopsy
5.3.2 Pelvic Ultrasound
5.3.3 Hysteroscopy
5.3.4 CT Scan
5.3.5 Other Diagnosis Methods
5.4 Geography
5.4.1 North America US Canada Mexico
5.4.2 Europe Germany UK France Italy Spain Rest of Europe
5.4.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle East & Africa GCC South Africa Rest of Middle East & Africa
5.4.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Sun Pharmaceuticals
6.1.2 Mylan
6.1.3 AstraZeneca Plc
6.1.4 Novartis AG
6.1.5 Bristol-Myers Squibb Company
6.1.6 R-Pharm-US LLC.
6.1.7 Pfizer Inc.
6.1.8 Elekta AB
6.1.9 Varian Medical Systems, Inc.

Note: Product cover images may vary from those shown
3 of 5


4 of 5
  • Sun Pharmaceuticals
  • Mylan
  • AstraZeneca Plc
  • Novartis AG
  • Bristol-Myers Squibb Company
  • R-Pharm-US LLC.
  • Pfizer Inc.
  • Elekta AB
  • Varian Medical Systems, Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4520057